The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its ...

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for Libtayo (cemiplimab), to be used as an adjuvant treatment for adults with cutaneous squamous cell carcinoma ...

Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...

Regeneron is expanding its pharmaceutical production in New York, joining a wave of drug companies growing domestic manufacturing in the wake of President Donald Trump’s tariffs. The move is a boon to ...

Each SOP document is a unit of risk,” said Paul Mathews, director of product management at CSC. “When the volume rises, there ...

Thanks so much, everyone. It's funny. I had -- I was talking to an investor, and he -- it was his first time in London. He goes, it's not that crowded. And I think it's going to be okay, and I told ...

When Carmen Thomas was growing up in Boston, her mom told her that her absent dad’s name was Joe Brown. So when she sent a saliva sample to 23andMe in her 20s and got a match with a Brown, she was ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...